Semaglutide: The Breakthrough GLP-1 Semaglutide was the first GLP-1 drug to show double-digit percentage weight loss in large clinical trials
This is normal variation in individual response
[4] Baldwin, W
, The neuroinflammatory state induced by CGRP and other inflammatory peptides can affect the vestibulocochlear system through direct action of CGRP in the inner ear and the vasodilation/vasospasm of the cochlear blood supply induced by trigeminal activation
Still, they are also a result of mitochondrial dysfunction, which occurs when mitochondria lose the protection of GSH, free radicals attack the mitochondria, and cellular energy decreases.8 Autoimmune conditions like multiple sclerosis, Crohns disease, rheumatoid arthritis, diabetes, Lyme disease, heavy metal load, organotoxins, and more all have mitochondrial dysfunction, low levels of GSH, and profound fatigue